Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Triomics Raises $15M to Automate Oncology Workflows with GenAI-Powered Platform

NextEdge Admin

15 May 2024

3 min 22 sec

Triomics, a company spearheaded by co-founders Sarim Khan and Hrituraj Singh, has recently secured $15 million in funding to revolutionize cancer care workflows. Their innovative approach combines generative AI and specialized software to address the cumbersome process of manually sifting through patient health records in oncology settings.

The company’s flagship product, OncoLLM™, is a specialized generative AI model tailored for oncology. By leveraging this technology, Triomics aims to automate the arduous task of screening patients for clinical trials and care pathways. This not only saves time but also ensures that patients receive timely access to potentially life-saving treatments.

Sarim Khan, CEO of Triomics, emphasizes the importance of their solutions sounding like experts in oncology. This commitment to accuracy and expertise is evident in their collaboration with leading academic cancer centers and researchers to develop benchmarks and best practices for generative AI in oncology.

Triomics’ software suite includes tools like Triomics Prism and Triomics Harmony, which integrate with health system electronic health records (EHRs) to streamline various clinical and administrative tasks. These tools aid in patient-trial matching, quality reporting, cohort analysis, and precision oncology, among other functions.

The company’s success lies in its deliberate investment in core areas of focus, blending AI expertise with clinical insights from oncology specialists. This synergistic approach ensures that their software not only performs optimally but also addresses the nuanced complexities of cancer research and care.

Triomics stands out from competitors by building tailored models specifically for oncology, rather than relying on broad-based solutions that may lack scalability or return on investment. Their dedication to advancing cancer care is underscored by partnerships with industry leaders and ongoing efforts to publish data on the efficacy of their solutions across diverse settings and patient populations.

With backing from prominent venture capital firms like Lightspeed and Nexus Venture Partners, Triomics is poised to deliver significant value to cancer care providers and patients worldwide. Their mission to leverage generative AI to streamline cancer center workflows marks a significant step forward in the quest to improve outcomes in oncology.